Alexander

When markets are fair and honest, companies can raise capital more efficiently, and investors – large and small – can participate with confidence. I’ve successfully prosecuted some of the largest, most complex securities fraud cases in history, recovering more than $2.5 billion on behalf of injured investors. Over the course of my career, I’ve repeatedly seen how strong private enforcement of the securities laws benefits investors in ways that flow through to the broader economy: it deters misconduct, incentivizes transparency, and helps ensure that markets function as they should. That’s why I remain committed to holding wrongdoers accountable, and why I am proud to help safeguard the integrity of our financial system.

Overview

Abe Alexander is a principal at Grant & Eisenhofer, where he focuses on securities fraud litigation.

Prior to joining G&E, Mr. Alexander helped recover over $1.06 billion on behalf of injured investors as a principal member of the trial team prosecuting In re Merck Vioxx Securities. The case, which asserted claims arising out of the Defendants’ alleged misrepresentations concerning the safety profile of Merck’s pain-killer, VIOXX, was settled shortly before trial and after more than 10 years of litigation, during which time plaintiffs achieved a unanimous and groundbreaking victory for investors at the U.S. Supreme Court. The settlement is the largest securities recovery ever achieved against a pharmaceutical company.

Mr. Alexander was a principal member of the trial team that prosecuted In re Schering-Plough Corp./ENHANCE Securities Litigation and In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation, which settled on the eve of trial for a combined $688 million. This $688 million settlement represents the second largest securities class action recovery against a pharmaceutical company in history.

Prior to joining G&E, Mr. Alexander was a partner at a New York firm representing institutional investors in securities and corporate governance litigation.

Areas of Focus

Experience

  • Recovered $1.06 billion in In re Merck Vioxx Securities Litigation, representing the largest securities fraud recovery against a pharmaceutical company in history.
  • Recovered $688 million on behalf of investors in Schering-Plough and Merck, representing the second largest securities fraud recovery against drug companies in history.
  • Secured a $450 million recovery in In re Kraft Heinz Securities Litigation, a case arising from alleged misstatements concerning the sustainability of Kraft Heinz’s cost-cutting measures and its brand investment and operations.
  • Secured a $149 million recovery on behalf of investors in Equifax, Inc., helping to lead a securities class action arising from one of the largest data breaches in American history.
  • Lead role in securing a $150 million settlement of investors’ claims against JPMorgan Chase arising from alleged misrepresentations concerning the trading activities of the so-called “London Whale.”
  • Secured a $95 million recovery on behalf of investors in Cognizant Technology Solutions dealing with alleged false statements and illegal payments to Indian governmental officials to secure favorable permits.

Obtained several additional significant recoveries on behalf of investors in pharmaceutical and life sciences companies, including:

  • a $142 million recovery in Medina v. Clovis Oncology, Inc., a securities fraud class action arising from Defendants’ alleged misstatements about the efficacy and safety of its most important drug;
  • a $77.5 million recovery in In re Myriad Genetics, Inc. Securities Litigation, a case arising from alleged misstatements concerning genetic testing products;
  • a $55 million recovery in In re HeartWare International, Inc. Securities Litigation, a case arising from Defendants’ alleged misstatements about the device-maker’s compliance with FDA regulations and the performance of its key heart pump;
  • a $44 million recovery in In re Adeptus Health Inc. Securities Litigation, a case arising from alleged misstatements concerning the liquidity and cash flow of the country’s largest operator of freestanding emergency rooms; and
  • a $39 million recovery in In re BioMarin Pharmaceutical Inc. Securities Litigation, a case arising from alleged misstatements concerning FDA review of a biologic.

Credentials

Education

  • University of Colorado Law School (JD)
    • Order of the Coif
  • New York University (BA, cum laude)

Admissions

  • New York
  • Delaware
  • US Court of Appeals for the 1st Circuit
  • US Court of Appeals for the 2nd Circuit
  • US Court of Appeals for the 3rd Circuit
  • US District Court for the District of Delaware
  • US District Court for the Southern District of New York
  • US District Court for the Eastern District of New York

Clerkship

  • Clerk to Chief Justice Michael L. Bender of the Colorado Supreme Court

Recognitions

  • National Law Journal, 2022 “Rising Star of the Plaintiff’s Bar”
  • Law360, 2021 “Rising Star”
  • Benchmark Litigation, “Future Star” and “40 & Under Hot List”
  • Lawdragon, “500 X – The Next Generation” and “500 Leading Plaintiff Financial Lawyers”
  • Super Lawyers, regular selection

Publications & Presentations

  • Biostatistics for Lawyers, Celesq
  • Statistics and Damages, PLI